Journal
PHARMACOGENOMICS
Volume 15, Issue 15, Pages 1893-1901Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.14.141
Keywords
CYP2C19; pharmacogenetics; pharmacokinetics; proton-pump inhibitors
Categories
Funding
- Fundacion Teofilo Hernando
- Fundacion de Investigacion Biomedica del Hospital Universitario de la Princesa
Ask authors/readers for more resources
Aim: To evaluate the possible association between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, rabeprazole and pantoprazole. Materials&methods: 151 healthy volunteers were evaluated for polymorphisms in the CYP2C19 gene using real-time polymerase chain reaction. Plasma concentrations were measured using high-performance liquid chromatography coupled to mass spectrometry. Results: Carriers of the *2 allele displayed poor metabolism for all the PPIs studied (around 50% decrease in clearance). Subjects with the *17 allele showed a light increase in clearance compared with *1/*1 (not significant). Conclusion: CYP2C19*2 is associated with decreased clearance of all the PPIs, that could be associated with higher drug efficacy. CYP2C19*17 could increase clearance of these drugs, although the effect seems small.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available